2024 FSHD Society International Research Congress Interim results from FORTITUDE™, a randomized Phase 1/2 trial evaluating AOC 1020 in adults with FSHD Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement
